All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: SVB Leerink
Deal Size: $190.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 11, 2021
Details:
Prometheus' lead candidate PRA023 is an IgG1 humanized mAb that has been shown to block TL1A. PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity to substantially improve outcomes for moderate-to-severe IBD patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Celerion
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
PRA023, the company's lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olanzapine
Therapeutic Area: Gastroenterology Product Name: STAR-OLZ
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Haisco Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2021
Details:
Under the terms of the agreement, Starton will receive an undisclosed upfront cash payment and is eligible to receive additional development and regulatory milestone payments, plus double-digit royalties on annual net sales of STAR-OLZ in the territory.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
In the Phase 1 SAD trial, MORF-057 was well tolerated in all 5 cohorts receiving MORF-057 in single doses ranging from 25 mg to 400 mg with no serious adverse events (SAEs) and no significant lab abnormalities in any subject.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: PT101
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
